Fate Therapeutics announced that the FDA has cleared its IND application for FT839, a next-generation, off-the-shelf CAR T-cell therapy co-targeting CD19 and CD38. The company plans to initiate a Phase 1/2 basket trial across…
AbbVie will present 21 abstracts at EHA 2026 spanning multiple myeloma, DLBCL, follicular lymphoma, CLL, AML, and AL amyloidosis. The most important readout is etentamig (ABBV-383) in patients previously exposed to BCMA-directed therapies, a…
The FDA has extended the review timeline for Orca Bio’s biologics license application (BLA) for Orca-T, a high-precision allogeneic cell therapy for hematologic malignancies. The updated PDUFA date has been moved from April 6,…
